Advanced

Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry

Molin, Daniel; Linderoth, Johan LU and Wahlin, Björn Engelbrekt (2017) In British Journal of Haematology 177(3). p.449-456
Abstract

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+ lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival,... (More)

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20+ lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P < 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Gender differences, Nodular lymphocyte predominant Hodgkin lymphoma, Population-based analysis, Rituximab, Survival
in
British Journal of Haematology
volume
177
issue
3
pages
449 - 456
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • scopus:85013797108
ISSN
0007-1048
DOI
10.1111/bjh.14567
language
English
LU publication?
no
id
f1d460a6-1694-4cd3-a657-b01df9443c91
date added to LUP
2017-03-09 13:38:46
date last changed
2018-01-30 12:22:09
@article{f1d460a6-1694-4cd3-a657-b01df9443c91,
  abstract     = {<p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20<sup>+</sup> lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P &lt; 0·00005), as did 10-year survival, 53% vs. 72% (multivariate P = 0·027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.</p>},
  author       = {Molin, Daniel and Linderoth, Johan and Wahlin, Björn Engelbrekt},
  issn         = {0007-1048},
  keyword      = {Gender differences,Nodular lymphocyte predominant Hodgkin lymphoma,Population-based analysis,Rituximab,Survival},
  language     = {eng},
  month        = {02},
  number       = {3},
  pages        = {449--456},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {British Journal of Haematology},
  title        = {Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry},
  url          = {http://dx.doi.org/10.1111/bjh.14567},
  volume       = {177},
  year         = {2017},
}